201 related articles for article (PubMed ID: 24488012)
1. Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer.
Teles Alves I; Hartjes T; McClellan E; Hiltemann S; Böttcher R; Dits N; Temanni MR; Janssen B; van Workum W; van der Spek P; Stubbs A; de Klein A; Eussen B; Trapman J; Jenster G
Oncogene; 2015 Jan; 34(5):568-77. PubMed ID: 24488012
[TBL] [Abstract][Full Text] [Related]
2. Retention of Interstitial Genes between
Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
[No Abstract] [Full Text] [Related]
3. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
[TBL] [Abstract][Full Text] [Related]
4. Genetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements.
Ramanand SG; Mani RS
Adv Exp Med Biol; 2019; 1210():57-66. PubMed ID: 31900904
[TBL] [Abstract][Full Text] [Related]
5. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
[TBL] [Abstract][Full Text] [Related]
6. A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in cancer.
Alves IT; Cano D; Böttcher R; van der Korput H; Dinjens W; Jenster G; Trapman J
Oncotarget; 2017 Jan; 8(4):6043-6056. PubMed ID: 27907910
[TBL] [Abstract][Full Text] [Related]
7. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1.
Liu B; Gu X; Huang T; Luan Y; Ding X
Oncol Rep; 2017 Jan; 37(1):201-208. PubMed ID: 28004109
[TBL] [Abstract][Full Text] [Related]
8. Novel transcription-induced fusion RNAs in prostate cancer.
Zhao S; Løvf M; Carm KT; Bakken AC; Hoff AM; Skotheim RI
Oncotarget; 2017 Jul; 8(30):49133-49143. PubMed ID: 28467780
[TBL] [Abstract][Full Text] [Related]
9. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.
Weier C; Haffner MC; Mosbruger T; Esopi DM; Hicks J; Zheng Q; Fedor H; Isaacs WB; De Marzo AM; Nelson WG; Yegnasubramanian S
J Pathol; 2013 Jun; 230(2):174-83. PubMed ID: 23447416
[TBL] [Abstract][Full Text] [Related]
10. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
11. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
13. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
[TBL] [Abstract][Full Text] [Related]
14. Analysis of fusion gene expression in prostate tumors by using single-end reads.
Xie DD; Li JY; Wang Y; Chen L; Yu DX
Genet Mol Res; 2013 Aug; 12(3):2886-94. PubMed ID: 24065644
[TBL] [Abstract][Full Text] [Related]
15. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
18. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.
Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A
BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414
[TBL] [Abstract][Full Text] [Related]
19. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
[TBL] [Abstract][Full Text] [Related]
20. Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration.
Rao SR; Alham NK; Upton E; McIntyre S; Bryant RJ; Cerundolo L; Bowes E; Jones S; Browne M; Mills I; Lamb A; Tomlinson I; Wedge D; Browning L; Sirinukunwattana K; Palles C; Hamdy FC; Rittscher J; Verrill C
J Mol Diagn; 2020 May; 22(5):652-669. PubMed ID: 32229180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]